Pulmotect announced that it has raised $5.9 million in a Series C funding to support a Phase 2 trial of the company's PUL-042 immunostimulant inhalation solution. According to Pulmotect, the new funds will be used along with an $8.9 million Product Development Research grant awarded last year by the Cancer Prevention and Research Institute of Texas (CPRIT) for the … [Read more...] about Pulmotect raises $5.9 million in Series C funding to support Phase 2 trial of PUL-042 inhalation solution in cancer patients
News
MannKind gets go-ahead for Phase 3 ICoN-1 trial of MNKD-101 clofazimine inhalation suspension in for NTM Japan
MannKind Corporation announced that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has cleared the initiation of the Phase 3 ICoN-1 trial of MNKD-101 clofazimine inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The company noted that the trial has already been cleared in the US, South Korea, and Australia; and … [Read more...] about MannKind gets go-ahead for Phase 3 ICoN-1 trial of MNKD-101 clofazimine inhalation suspension in for NTM Japan
Synairgen names Mark Parry-Billings as new Chairman of the Board
UK-based Synairgen, which is developing SNG001 inhaled interferon-beta-1a, announced that former Chiesi Global Head of Drug Development Mark Parry-Billings will succeed Simon Shaw as Chairman of the Board. Shaw will retire in October 2024. Prior to joining Chiesi in 2011, Parry-Billings was CEO of Topigen Pharmaceuticals, which was sold to Pharmaxis in 2010. His … [Read more...] about Synairgen names Mark Parry-Billings as new Chairman of the Board
Ritedose to manufacture Verona’s Ohtuvayre inhaled ensifentrine
CDMO Ritedose Corporation announced that it will manufacture Verona Pharma's Ohtuvayre nebulized ensifentrine, which was approved by the FDA in June 2024 for the treatment of COPD. Also in June 2024, Ritedose announced that it was adding blow-fill-seal (BFS) capacity for an additional 180 million unit doses at its manufacturing facility in Columbia, SC, … [Read more...] about Ritedose to manufacture Verona’s Ohtuvayre inhaled ensifentrine
Serán Bio gets $200 million investment to support new commercial manufacturing facility
CDMO Serán Bioscience announced "a strategic growth transaction" led by Bain Capital Life Sciences that is worth more than $200 million, with the funds intended to support completion of a new commercial-scale manufacturing facility in Bend, Oregon, where the company is headquartered. According to Serán Bio, the commercial-scale facility, which is expected to be … [Read more...] about Serán Bio gets $200 million investment to support new commercial manufacturing facility
Vectura to be acquired by Phillips Medisize parent Molex
Inhalation CDMO Vectura has been sold to Molex for £150 million up front and up to an additional £148 million in potential payments, the companies have announced. Following the acquisition, Vectura will be operated by Phillips Medisize, which was acquired by Molex in 2016. The sale is expected to close by the end of this year. According to the Vectura Fertin press … [Read more...] about Vectura to be acquired by Phillips Medisize parent Molex
Nuance to market Altamira’s Bentrio bentonite-based nasal spray in additional Asian countries
Altamira Therapeutics has announced an extension of its 2022 license and distribution agreement that gave Nuance Pharma the rights to market Altamira's Bentrio nasal spray in China, Hong Kong, Macau and South Korea. According to Altamira, Nuance has recently submitted a marketing application for Bentrio in China. The revised deal adds Singapore, Malaysia, Thailand, … [Read more...] about Nuance to market Altamira’s Bentrio bentonite-based nasal spray in additional Asian countries
Leyden Labs names Jintanat Ananworanich as new Chief Medical Officer
Nasal drug developer Leyden Laboratories announced that former Moderna vaccine development executive Jintanat Ananworanich has joined the company as Chief Medical Officer. Ananworanich was most recently Executive Director of clinical development at Moderna, and her previous experience includes roles as Clinical Development Leader at the Bill and Melinda Gates Medical … [Read more...] about Leyden Labs names Jintanat Ananworanich as new Chief Medical Officer
TFF Pharmaceuticals partners with Emory University on mRNA-based antiviral DPI with BARDA funding
TFF Pharmaceuticals announced that it will study the feasibility of formulating Emory University's mRNA-based Cas13a antiviral for the treatment of SARS-CoV-2 and influenza A and B as a dry powder using the company's thin film freezing technology. Funding for the study is provided by the Biomedical Advanced Research and Development Authority (BARDA) as part of its … [Read more...] about TFF Pharmaceuticals partners with Emory University on mRNA-based antiviral DPI with BARDA funding
Human Factors (HF) Considerations for Generic Inhalers Using Off-the-shelf Devices
By Yvonne Limpens, Managing Human Factors Specialist at Emergo by UL While the time to market for generic inhalers is much shorter compared to novel inhalers because there is no requirement for generic product manufacturers to repeat clinical research on ingredients or dosage forms already approved for safety and effectiveness, one aspect often overlooked during … [Read more...] about Human Factors (HF) Considerations for Generic Inhalers Using Off-the-shelf Devices